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Allogenic BMTAbstract Objective: Our aim was to analyze brain MRI ﬁndings in pediatric patients who devel-
oped neurologic complications after allogeneic bone marrow transplantation.
Materials and methods: This prospective study included 33 consecutive patients (age range from 3
to 18 years, mean 11.8 ± 5.1 years). They were referred to the MRI unit because of the neurological
symptoms in the post transplant period. The underlying disorders included: non malignant hema-
tological disorders (n= 20, 60.6%) and hematological malignancies (n= 13, 39.4%). Onset of the
presentation of the complication in relation to the chronology of the transplant was identiﬁed in
each patient (phase1: from days 0 to 30, phase 2: from days 30 to 100, and late phase after day 100).
Results: According to the MRI ﬁndings 6 patients (18.2%) showed normal examinations. Twenty-
seven patients (81.8%) with positive MRI ﬁndings, are grouped into 7 main categories: posterior
reversible encephalopathy syndrome (n= 16, 48.48%), intracranial hemorrhage (n= 2, 6.06%),
cerebral venous sinus thrombosis (n= 1, 3.03%), CNS infection (n= 2, 6.06%), leukoencephalop-
athy (n= 5, 15.15%), mild atrophy (n= 11, 33.33%), CNS relapse (n= 1, 3.03%), with 9 patients
having more than one diagnosis. Ten cases of PRES and 1 case of sinus thrombosis were detected in
phase 1. Two cases of PRES and 2 cases of intracranial hemorrhage were detected in phase 2. Four
cases of leukoencephalopathy, 4 cases of PRES, 2 cases of CNS infection, and 1 case of CNS relapse
were detected in phase 3.
1266 S. Emad-Eldin, M. Abdel-MoetiConclusion: CNS complications after allogenic BMT in pediatric patients could cause a signiﬁcant
clinical problem. MRI can provide early diagnosis and follow-up to monitor treatment changes.
Knowing the onset of the presentation of the complication in relation to the chronology of the
transplant is important as it provides signiﬁcant guidance on which causes to consider.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1. Introduction
Bone marrow transplantation (BMT) is performed to restore
hematologic and immunologic competence for a range of
childhood hematologic malignancies (leukemia and malignant
lymphoma), as well as to treat congenital conditions in which
these functions are depressed or absent (1).
Before BMT, the patient is prepared with high doses of che-
motherapy, frequently associated with total-body irradiation,
to destroy the hematopoietic system and to suppress the
immune system, especially T-cells, so that graft rejection is pre-
vented. In addition in patients with hematological malignan-
cies, the preparative regimen also serves to reduce the tumor
burden (2). Such therapeutic regimens increase the risk of
patient morbidity and mortality in both the short and long
terms (1).
Complications in the post transplantation period are
mostly related to hematopoietic and immune system aplasia
and to the allo-reactivity of donor cells. Because preparative
regimens destroy the recipient immune and hematopoietic
systems, immunologic recovery depends on engraftment and
proliferation of the infused stem cells (3).
The immune status of children after BMT can be divided
into three phases: the pre-engraftment period (days 0–30),
the post-engraftment period (days 30–100), and the late phase
(after day 100). The timing of CNS complications that occur
after BMT, as for complications in other organs, can be
described with reference to these three phases of immune status
(2).
The most common and clinically signiﬁcant complications
are infection, vascular disorders, therapy-induced cytotoxicity,
graft versus-host disease (GVHD), and recurrence of preexist-
ing diseases (3).
Early diagnosis is crucial to successful management and
good prognosis, because CNS complications are potentially
devastating. CT and MRI play an important role in early diag-
nosis, which maximizes the chance of prompt therapy for
transplantation-related complications (3).
In the present study, we prospectively evaluated MRI ﬁnd-
ings in central nervous system complications in children after
allogenic bone marrow transplantation with correlation from
the onset of presentation to the post transplant period.
2. Material and methods
The study was approved by the hospital ethics committee. This
prospective study included 33 consecutive patients who were
referred to the MRI unit at our institution between July
2010 and December 2013 because of the neurological CNS
symptoms that required MRI imaging evaluation afterallogeneic BMT. There were 10 females and 23 males, ranging
in age from 3 years to 18 years (mean 11.8 ± 5.1 years). All
patients did allogenic BMT from HLA matched related
donors.
The underlying disorders included: severe aplastic anemia
(n= 7), Fanconi anemia (n= 4), beta thalassemia (n= 8),
severe combined immunodeﬁciency (SCID) (n= 1), chronic
myelogenous leukemia (n= 1), acute myelogenous leukemia
(n= 4) and acute lymphocytic leukemia (n= 8) (Table 1).
The neurological clinical symptoms that required MRI
examination are presented in Table 2. Seizure was the most
common presenting symptom in 11 patients (33.3%) followed
by altered mental status in 8 patients (24.2%), visual distur-
bance in 6 patients (18.2%), severe headache in 5 patients
(15.15%), motor weakness in 2 patients (6.1%), and paresthe-
sia in 1 patient (3.03%). Onset of the presentation of the com-
plication in relation to the chronology of the transplant was
identiﬁed in each patient.
3. Methods
MR examinations were performed on two MRI machines: 3-T
MR scanner (Gyroscan Intera, Philips medical systems, Neth-
erlands) and 1.5 T MR scanner (Signa, General Electric,
USA). MR imaging protocol included sagittal and axial
T1WI, T2WI and FLAIR images in the axial plane. Contrast
T1WI in axial, coronal and sagittal planes was obtained after
injection of 0.1 mol Gadopentetate dimeglumine-DTPA
(Magnevist; Schering, Berlin, Germany). Diffusion-weighted
images (DWIs) and apparent diffusion coefﬁcient (ADC) maps
were obtained. Seventy-two MRI examinations were per-
formed (9 patients had 1 study each; with 24 patients having
more than 1 study: 18 patient had 2 studies; 1 patient had 3
studies; 4 patients had 4 studies and 1 patient had 6 studies).
Follow-up MRI examinations were performed at variable
intervals according to the patient clinical condition.
MRA and MRV examinations were performed in 7 patients
due to clinical suspicion of vascular complications. Contrast
enhanced studies were performed in all cases to exclude
infection.
4. Conditioning regimen and preventive measures
The conditioning regimen for each patient depended on the
underlying disease, type of donor and graft, and comorbidities.
GVHD prophylaxis consisted of Cyclosporin A (CsA) com-
bined with one of the following: methotrexate or corticoste-
roid. The target serum concentration of CsA was 200 ng/mL.
All patients received antibacterial, antiviral and antifungal
prophylaxis from the day of admission.
Table 1 Clinical indications of bone marrow transplantation
in 33 children included in the study.
Number Percentage (%)
Acute myelogenous leukemia 4 12.12
Chronic myelogenous leukemia 1 3.03
Acute lymphocytic leukemia 8 24.24
Beta thalassemia 8 24.24
Severe aplastic anemia 7 21.21




Table 2 Clinical presentations in 33 children after allogenic
BMT.
Neurological symptoms No Percentage (%)
Seizures 11 33.30
Altered mental status 8 24.20
Visual disturbance 6 18.20
Severe headache 5 15.15
Motor weakness 2 6.06
Paresthesia 1 3.03
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The MRI diagnoses of the patients in relation to the chronol-
ogy of BMT are demonstrated in Table 3. Among the 33
patients included in the study, 6 patients (18.2%) showed nor-
mal MRI brain ﬁndings, those patients presented with non
repetitive neurological symptoms. Twenty-seven patients
(81.8%) showed positive MRI ﬁndings, they were grouped into
7 main categories:
5.1. Calcineurin inhibitor (CNI)-induced toxicity
Sixteen patients were diagnosed as posterior reversible enceph-
alopathy syndrome (PRES) associated with CNI-induced tox-
icity. The level of CsA at the onset of PRES presentation was
reviewed, the serum level of CsA was slightly elevated in only
6/16 patients (37.5%). Hypertension associated with PRES
was detected in 5/16 patients.Table 3 MRI ﬁndings in 33 children after allogenic BMT with the
MRI ﬁndings Phase 1 Phase 2









a Nine patients had more than one diagnosis.PRES lesions were identiﬁed in FLAIR images and their
distribution in anatomical regions was made. The anatomi-
cal regions were identiﬁed as frontal, parietal, occipital and
temporal lobes as well as corpus callosum, basal ganglia
and cerebellum. Gadolinium enhancement was identiﬁed if
any.
The most frequently affected regions on FLAIR were the
parieto-occipital region in 3/16 (18.75%), posterior parietal
lobes in 3/16 (18.75%), occipital lobes in 2/16 (12.5%).
(Fig. 1) Thus 50% were in the posterior regions. Holo-hemi-
spheric affection (involvement of the frontal, parietal, tempo-
ral and occipital regions) was detected in 7/16 (43.75%).
(Fig. 2) Additional cerebellar affection was detected in 3/18
(18.75%), whereas basal ganglia and corpus callosum involve-
ment were detected in 1/18 (6.25%) and 2/18 (12.5%)
respectively.
Ten out of 16 cases (62.5%) diagnosed with PRES were
detected in the early post transplant period (phase 1), whereas
2/16 cases (12.5%) were detected in phase 2 and 4/16 cases
(25%) were detected in phase 3.
Contrast enhancement was detected in 2/16 (12.5%). The
initial scan showed leptomeningeal enhancement which was
resolved in follow up examinations.
Hemorrhagic changes were detected in 2/16 cases (12.5%).
Initial MRI study showed minimal sulcal SAH in 1 case
whereas in the other case, minute focal hemorrhage was
detected in the follow up MRI examination (Fig. 3).
In follow up MRI, signal changes usually completely
reverse in 15/16 cases (93.75%), with 1 case (6.25%) showing
persistent signal changes. Recurrent PRES was found in 1 case
(6.25%) who developed two episodes of PRES, 6 and 9 months
after the ﬁrst one. Two patients were initially diagnosed with
PRES died due to acute GVHD.
5.2. Cerebrovascular hemorrhage
Intracranial hemorrhage was detected in 2 patients (6.06%).
Parenchyma cerebral and cerebellar hematomas together with
SAH were detected in one patient 40 days post transplant
(phase 2) (Fig. 4). Follow up MRI done later showed resolu-
tion of the SAH and cerebellar hematomas, with decrease in
the size of cerebral hematoma.
Intraventricular hemorrhage was detected in one patient
2 months post transplant (phase 2), this patient died within
24 h after hemorrhage detection.ir relation to the chronology of transplantation.










Fig. 1 Posterior reversible encephalopathy syndrome (PRES) in
a 9 year-old male patient after BMT for beta thalassemia,
presented with sudden seizure on day 25 post transplant. He had
been treated with MTX and cyclosporine as prophylaxis from
GVHD. Axial FLAIR MR image shows bilateral occipital
cortical-subcortical abnormal hyperintense lesions. These imaging
appearances are typically consistent with PRES.
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Superior sagittal sinus (SSS) thrombosis was detected in one
patient (3.03%), 5 days post transplant (phase 1). Recanaliza-
tion of the occluded sinus was detected in follow up serial MRI
done 5 and 22 days later.Fig. 2 Posterior reversible encephalopathy syndrome (PRES) in a 1
treated with MTX and cyclosporine as prophylaxis from GVHD. He e
6 months after BMT (a) Axial FLAIR and (b) Coronal T2WI show
regions, splenium together with the cerebellum which is rarely see
examination done 2 weeks later, the patient died due to acute GVHD5.4. Cerebral infection
In the current study 2 patients (6.06%) developed cerebral
infection (one case of fungal aspergillosis (Fig. 5) and one case
of toxoplasmosis (Fig. 6)). Both cases were diagnosed
6 months (phase 3) after BMT.
5.5. Leuko-encephalopathy
Leuko-encephalopathy was detected in 2 patients (6.06%) as
an isolated ﬁnding, whereas it was detected in 3 patients
(9.09%) combined with other diagnosis (PRES (n= 1),
relapse (n= 1), and cerebral venous thrombosis (n= 1)).
The extent of the lesions was visually graded from 1 to 3
according to the US national Cancer Institute grading of leu-
koencephalopathy as grade 1: high focal periventricular, grade
II: focal periventricular extending to the centrum semiovale,
and grade III: conﬂuent total white matter (4). According to
this classiﬁcation: 3 patients were classiﬁed as grade I, 1 patient
as grade II and 1 patient as grade III (Fig. 7)
5.6. Mild brain atrophy
Isolated mild atrophic brain changes and volume loss were
detected in 3 patients (3.03%), atrophic brain changes were
detected in combination with 5 cases of leukoencephalopathy,
and 3 cases of PRES.
5.7. CSN relapse
Relapse was diagnosed in one patient (3.03%) who did BMT
for AML. The CNS relapse was detected 1 year after trans-
plantation. MRI showed orbital and leptomeningeal soft tissue
masses (Fig. 8). The relapsing disease showed a ﬂuctuating3 year-old male patient after BMT because of CML. He had been
xperienced sudden onset of seizures and disturbed conscious level
patchy hyperintense lesions at both frontal and parieto-occipital
n. Although the lesions markedly regressed in follow up MRI
.
Fig. 3 Posterior reversible encephalopathy syndrome (PRES) in a 5-year-old boy after BMT because of beta thalassemia. He had been
treated with CSA, steroid and MTX as prophylaxis of GVHD. He had been diagnosed with PRES on day 21 post transplant. Follow up
MRI done 1 month later, showed residual areas of high T2 signal at both frontal regions (b) with tiny hemorrhagic foci of high T1
signal (c).
Fig. 4 Cerebral hemorrhage in an 8 year-old female patient after
allogenic BMT for Fanconi anemia, presenting with a sudden
seizure on day 40 post transplant. Axial T1WI shows small
subacute hematoma at the right parietal region.
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periventricular lesions in the follow up MRI done 2 years after
the initial examination.
Out of the 33 patients with CNS complications, 5 patients
(15.15%) died after BMT. The death of 3 patients was consid-
ered a direct result of CNS complications: intracranial hemor-
rhage in 2 patients and CNS infection in 1 patient. The
remaining 2 patients died because of acute GVHD.6. Discussion
CNS complications have been found more frequently in alloge-
neic stem cell transplantation than in autologous or syngeneic
stem cell transplantation (3). The frequency of CNS involve-
ment associated with BMT is reported to be 11–65% (90%
at autopsy) of BMT recipients, and these CNS complications
may be the main causes of death in 9–17% (1,5,6). Immediate
and comprehensive diagnostic work-up, especially neuroimag-
ing, is required to detect neurological events in any patients
presenting with neurological symptoms (7). Thus early recog-
nition of these complications with imaging and appropriate
management will allow early intervention with immunother-
apy or additional chemotherapy to improve the chance of sur-
vival (3).
In this study we presented different MRI imaging abnor-
malities of the central nervous system complications in pediat-
rics after allogeneic BMT. The ﬁndings of this study are in
accordance with previous clinical studies (2,3,8) which demon-
strated the effectiveness of MRI in early diagnosis of CNS
complications in the post transplantation period after BMT.
To reach a proper diagnosis, it is essential for the radiolo-
gist to understand how imaging ﬁndings correlate with the
clinical feature (2). On the other hand knowing the onset of
the presentation of the complication in relation to the chronol-
ogy of the transplant is important, as it was useful for narrow-
ing the differential diagnosis (9).
In the current study CNI-induced neurotoxicity was the
most common complication, as 16 patients (48.5%) were diag-
nosed with PRES. PRES is a clinico-neuro-radiologic disease
entity represented by characteristic MR imaging ﬁndings of
subcortical and cortical hyperintensity on T2WI, most often
in the parieto-occipital lobes, accompanied by clinical neuro-
logic alterations ranging from headache, altered mental status,
seizures, and vision loss, to the loss of consciousness (10).
Fig. 5 Cerebral aspergillosis in a 16 year-old-boy after BMT due to severe aplastic anemia. He presented with headache and altered
mental status 4 months post transplant. Three serial MRI studies were obtained. (a) and (b) Axial T1 and T2WI show left parietal
irregular shaped lesion with a peripheral rim of high T1 and low T2 signal. (c) Post contrast axial T1WI shows marginal enhancement of
the lesion. Brain MR imaging was repeated 30 days after the initial study (d), which shows progression of the lesion with increase in its
size, surrounding edema and newly depicted midline shift. The core of the lesions shows high T1 signal denoting hemorrhage. Stereotactic
drainage with intra-lesional administration of Amphotericin B was performed. A third MR imaging study was obtained 57 days after the
initial study (e) shows shrinkage size of the lesion, with intralesional air, likely sequel of previous intervention. Despite aggressive
antimicrobial treatment, the patient died of complication 6 months after the initial diagnosis of aspergillosis.
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were detected early in the post transplant period (phase1), with
37.5% detected in phases 2 and 3. Similarly Dhar and Human,
have reported that although drug toxicity tends to occur early,
yet it may occur at any point while the patient is on immuno-
suppressant therapy (9).
MRI examinations showed typical features of PRES and
less commonly affected regions such as cerebellum and basal
ganglia, with the most frequently affected areas of the brain
being the posterior regions. This was in accordance with the
ﬁndings of previous studies (11–13).
Atypical MR imaging appearances which include contrast
enhancement and hemorrhage were detected in 4/16 patients
(25%). Gyral and leptomeningeal enhancement was previously
reported, and this was interpreted as leakage due to direct
endothelial injury causing blood–brain barrier breakdown
(12,13). Hefzy and his colleagues previously described three
distinct types of hemorrhage, including focal minute hemor-
rhages, larger more typical focal hematomas, and sulcal-based
subarachnoid hemorrhage (14).
The level of CsA at the onset of PRES presentation was
reviewed, the serum level of CsA was slightly elevated in only
6/16 patients (37.5%). This was supported by the previous
ﬁndings of Koh et al. (7) and Weber et al. (8). The lack of
direct correlation between CsA level and CsA induced neuro-
toxicity was perviously described (15).
Although hypertension is a risk factor for PRES, yet blood
pressure may be normal in some cases, particularly in the set-
tings of chemotherapy, and immunosuppressive therapy (10).
This is strongly supported by our data, as only few cases
who presented with PRES are associated with hypertension.
GVHD was the primary cause of death in 2 patients ini-
tially diagnosed with PRES. This was in accordance with the
previous studies (7,11,16). The discontinuation of CNI admin-
istration may cause poor prevention and management of
GVHD resulting in signiﬁcant mortality due to GVHD. Thus
decisions on the changes in the immunosuppressive agent
should be made carefully in order to balance the control of
GVHD and the management of CNI-associated neurotoxicity
(7).
Cerebral venous sinus thrombosis should be considered in
the differential diagnosis when neurological symptoms occur
following BMT (17). In our study 1 case (3.03%) complained
of headache on day 5 post transplant, and MRV showed
thrombosis of the superior sagittal sinus, which recanalized
in the follow up studies. For the diagnosis of venous thrombo-
sis, the combination of MR imaging with MRV is now the
method of choice because of its capability to reveal a lack of
ﬂow in the cerebral veins even with the absence of typical ﬁnd-
ings of brain infarcts (18). Whereas the thrombus is easily rec-
ognizable in the subacute phase, it can be mistaken for ﬂowing
blood in the acute phase, but MRV will demonstrate the
absence of ﬂow (10).
In this study, MRI accurately detected extra-axial and
parenchyma hemorrhage in 2 cases (6.06%). Cerebrovascular
disease occurs in 3.8–8.8% of BMT recipients (more than
50% at autopsy), mostly during the ﬁrst or second phase after
BMT (1,6,19). Subdural hemorrhage is most common, reﬂect-
ing thrombocytopenia. Intraparenchymal hemorrhage, sub-
arachnoid hemorrhage, and infarction may also develop (2).
Another complication after BMT is infectious disease. The
use of more potent and effective immunosuppressive regimenshave reduced the risk of graft rejection but increased the sus-
ceptibility of transplant recipients to a variety of opportunistic
CNS infections (9).
In imaging of brain abscess post BMT, ring enhancement is
often absent reﬂecting the deﬁciency of the inﬂammatory
response caused by severely immunocompromised status,
whereas in less severe immunocompromised status, there
may be ring like enhancement (2). Nishiguchi et al., have sug-
gested that brain abscess should be considered in the diagnosis
of hypodense cerebral parenchymal lesion, even if there are
minimal mass effect and negligible enhancement (3). However
in our series the 2 patients who diagnosed with CNS infection
(6.06%), showed marginal enhancement of the brain lesions.
Aspergillosis is the most common CNS infection after
BMT, especially during the ﬁrst and second phases.(2) Early
diagnosis of invasive aspergillosis in immunocompromised
patient remains a major challenge (8). The organism is rarely
cultured from cerebrospinal ﬂuid, so the clinical diagnosis of
cerebral aspergillosis can be difﬁcult (2). Although typical
MRI ﬁndings have been described, appearance of cerebral
lesions may be too late for a successful treatment. Thus, the
diagnosis is usually delayed (8).
In this study one patient suffered from cerebral aspergillo-
sis, the diagnosis was ultimately made by the typical MRI ﬁnd-
ings as the lesion showed a central core of hypointense T1
signal, with a rim of high T1 and low T2 signal. This was in
accordance with the previous ﬁndings of Weber et al. (8).
Shortened T1 relaxation times and the zones of low signal
intensity at the periphery of the lesion on T2WI are attributed
to the presence of iron, manganese, and magnesium in the fun-
gal concretions (20,21). However Tempkin and his colleagues
attributed these ﬁndings to areas of hemorrhage (22).
Previous clinical studies have suggested that clinicians
should exclude the presence of coexisting pulmonary or sinus
infections (23–25). In our case, CT examinations of the chest
and sinuses were performed to exclude pulmonary and sinus
aspergillosis, yet they were negative.
Cerebral toxoplasmosis is considered a rare but fatal com-
plication after BMT (25). It is usually seen after engraftment in
the early post transplantation period (8). Ionita et al., previ-
ously reported that toxoplasma encephalitis complicating
BMT, a lack of enhancement is occasionally encountered for
small nodular lesions or sometimes may be masked by T1
shortening due to hemorrhagic transformation in larger lesions
(26). In this study there was one case of toxoplasmosis mani-
fested as wide spread cerebellar and cerebral lesions, primarily
at the gray white matter interface and basal ganglia, with min-
imal hemorrhagic signal in few lesions. MRI promoted early
diagnosis of the lesions, with the patient stabilized and sur-
vived after responding to proper antimicrobial treatment.
Among our patients, we had 5 cases (15.5%) diagnosed
with leukoencephalopathy, associated with mild atrophy and
volume loss. They received methotrexate in their conditioning
regimen, with total body irradiation (TBI) performed in 3 of
them who were initially diagnosed with ALL before BMT.
The prevalence of leukoencephalopathy post BMT is rang-
ing from 16 to 69%. Neurological symptoms may or may not
be present (2). Prophylactic chemotherapy using MTX can
cause leukoencephalopathy. The dose of intravenous MTX
correlates with the incidence of leukoencephalopathy, regard-
less of the history of radiation therapy (27). In addition radia-
tion therapy can produce white matter lesions, the possible
Fig. 6 Cerebral toxoplasmosis in a 7-year-old male patient after BMT due to severe aplastic anemia. He presented with altered mental
status 6 months post transplant (a) axial FLAIR image shows bilateral basal ganglia and gray matter–white matter interface hyperintense
lesions. (b) Axial T1WI shows small hemorrhagic signal in a right temporal lesion. (c) Coronal T1WI post contrast MR image shows
marginal enhancement of the lesions. Follow up MRI done 2 months later and axial FLAIR image (d) shows regression of the lesions after
proper antimicrobial treatment.
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culature within the brain and damage to the oligodendrocytes
that produce myelin, which result in an increase in brain water
with a loss of brain tissue (10).
In this study one patient who did BMT for ALL, was diag-
nosed with extramedullary CNS relapse one year post trans-
plant, the case showed intra-orbital, and leptomeningeal
lesions, with no associated medullary relapse.
The relapse of acute leukemia is less frequent after alloge-
neic than after autologous BMT and this is due to the graft-
versus-leukemia (GVL) effect that occurs after allogeneicBMT (28). However there is a relative higher frequency of
extramedullay relapse of acute leukemia than medullary
relapse. This is due to the GVL effect in extramedullary sites
of the body which may not be as effective as in the bone mar-
row (28).
In conclusion, CNS complications after allogenic BMT in
pediatric patients could cause a signiﬁcant clinical problem
in the post transplant period. To begin proper treatment as
early as possible, accurate diagnosis is important. MRI can
provide early diagnosis and follow-up to monitor treatment
changes. Knowing the onset of the presentation of the
Fig. 7 Leukoencephalopathy in an 18-year-old male patient
after allogenic BMT for AML. Axial FLAIR image shows
extensive bilateral areas of abnormal signal intensity involving
the white matter that are due to the previous combination of
chemotherapy and radiation therapy.
Fig. 8 CNS relapse in an 18-year-old female patient 1 year after
allogenic BMT for ALL. (a) Axial T1WI shows right orbital soft
tissue mass causing mild proptosis of the right eye globe, with
associated small right parasellar extra-axial leptomeningeal lesion.
Brain MRI abnormalities in pediatric patients after allogeneic bone marrow transplantation 1273complication in relation to the chronology of the transplant is
important as it provides signiﬁcant guidance on which causes
to consider.
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